I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the "Transaction") have been either satisfied or waived and accordingly, the Transaction has successfully closed.

I-Mab ( NASDAQ:IMAB ) Full Year 2023 Results Key Financial Results Net loss: CN¥1.47b (loss narrowed by 39% from FY...

I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.

Q4 2023 Summit Therapeutics Inc Earnings Call

I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarket trading. The company will sell its China unit, I-Mab Shanghai, to affiliate Hangzhou Co for up to $80 million, subject to certain regulatory and sales-based milestones. The move makes strategic sense, Cantor Fitzgerald analyst Louise Chen said, adding that the development came as a surprise.

I-Mab (the "Company") (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd. (the "Hangzhou Company"), an unconsolidated affiliate of the Company, and a group of China-based investors to divest t

Key Insights The considerable ownership by individual investors in I-Mab indicates that they collectively have a...

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, and HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BT